MedTrace Logo

Role of Dexmedetomidine as Synergistic Agent

NCT06662175 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2024-10-28

No results posted yet for this study

Summary

The aim of this clinical trial is to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.

Conditions

  • Dexmedetomidine
  • Hyperbaric Bupivacaine
  • Subarachnoid Anesthesia

Interventions

DRUG

Hyperbaric bupivacaine

Group A (Unexposed) will received 2 ml of intrathecal bupivacaine

DRUG

hyperbaric bupivacaine and dexmedetomidine

Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion

Sponsors & Collaborators

  • Lady Reading Hospital, Pakistan

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2025-07-31
Completion
2025-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06662175 on ClinicalTrials.gov